<DOC>
	<DOCNO>NCT01137474</DOCNO>
	<brief_summary>The purpose study learn whether dapagliflozin , 12 week , improve ( decrease ) blood pressure patient type 2 diabetes uncontrolled hypertension angiotensin-converting enzyme inhibitor angiotensin receptor blocker . The safety treatment also study .</brief_summary>
	<brief_title>A Study BMS-512148 ( Dapagliflozin ) Patients With Type 2 Diabetes Inadequately Controlled Hypertension Angiotensin-Converting Enzyme Inhibitor Angiotensin Receptor Blocker</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Key inclusion criterion Participants willing able give sign write informed consent Males female , age 18 89 year , type 2 diabetes inadequate glycemic control ( hemoglobin A1c 7 % 10.5 % ) uncontrolled hypertension ( seat systolic blood pressure 140 165 mm Hg seat diastolic blood pressure 85 105 mm Hg ) Mean 24hour BP &gt; =130/80 mmHg determine ABPM Stable dose oral antidiabetic agent ( OAD ) least 6 week ( 12 week thiazolidinedione ) stable daily dose insulin monotherapy combination another OAD , 8 week , stable dose angiotensinconverting enzyme inhibitor angiotensinreceptor blocker least 4 week Cpeptide level ≥0.8 ng/mL Body mass index ≤ 45.0 kg/m^2 Key exclusion criterion Aspartate aminotransferase alanine aminotransferase level &gt; 3*upper limit normal ( ULN ) Serum total bilirubin level &gt; 1.5*ULN Serum creatinine ≥2.0 mg/dL unless subject metformin , exclusionary limit serum creatinine ≥1.50 mg/dL men ≥1.40 mg/dL woman Estimated creatinine clearance &lt; 60 mL/min Hemoglobin ≤10.0 g/dL men ≤9.0 g/dL woman Creatine kinase &gt; 3*ULN Positive hepatitis B surface antigen Positive antihepatitis C virus antibody Abnormal free T4 value History diabetes insipidus Symptoms poorly control diabetes would preclude participation trial , include limited , mark polyuria polydipsia great 10 % weight loss 3 month prior enrollment . History diabetic ketoacidosis hyperosmolar nonketotic coma History malignant accelerate hypertension Known suspect secondary hypertension Any follow within 6 month enrollment visit : Myocardial infarction Cardiac surgery revascularization ( coronary artery bypass surgery /percutaneous transluminal coronary angioplasty ) Unstable angina Unstable congestive heart disease New York Heart Association Class III IV Transient ischemic attack significant cerebrovascular disease Unstable previously undiagnosed arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Angiotensin Receptor Antagonists</keyword>
	<keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>